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Summary Several 1,2-dithiol-3-thione and dithioester compounds were assayed for radioprotective
capabilities in EMT6 cells in vitro. The 1,2-dithiol-3-thiones were generally more cytotoxic than the dithioesters
and in some instances were more cytotoxic toward hypoxic cells than toward normally oxygenated cells. When
the drugs were present at a concentration of 50011M for 1 h prior to and during radiation delivery, the
5-(2-thienyl)-1,2-dithiol-3-thione produced a radiation protection factor (RPF) of 2.7 at 1 log of cell kill. The
4-methyl analogue of this same compound was, however, much less effective, producing a RPF of only 1.2.
The 4-ethoxycarbonyl analogue was moderately active, producing a RPF of 1.7. The 4-methyl-5-(2-pyrazinyl)-
1,2-dithiol-3-thione (Oltipraz) was least effective, yielding a RPF of only 1.1. Of the dithioesters tested, methyl
3-pyrrolidino-2-phenylpropene dithiocarboxylate produced a RPF of 2.6, methyl 3-piperidino-2-
phenylpropenedithiocarboxylate a RPF of 2.7, and the corresponding 3-morpholino and 3-thiomorpholino
derivatives RPF values of 2.7 and 2.9, respectively. The iodide salt of 4-ethoxycarbonyl-5-(2-thienyl)-1,2-
dithiol-3-thione produced a RPF of 2.6 Methyl 3-cyclohexylamino-2-phenylpropenedithiocarboxylate was
equally effective (RPF = 2.6). Finally, methyl 3-morpholino-3-thienyl-2-methylpropenedithiocarboxylate and
methyl 3-morpholino-3-(2-pyrazinyl)-2-methylpropenedithiocarboxylate were less effective, producing RPF
values of 2.0 and 1.6, respectively. These results demonstrate that several of these compounds are highly
effective radioprotectors. In vitro and in vivo studies testing their efficacy are underway.
In the search for methods to improve cancer therapy, one
experimental strategy that has been somewhat successful in
recent years is the use of normal tissue protectors. In the case
of radiation, these protective agents may improve the
therapeutic index by reducing toxicity and allowing higher
doses of radiation to be delivered to a tumour in the vicinity
of sensitive normal tissue. A large body of data exists on the
use of thiol compounds as both radiation and chemoprotec-
tive drugs. One such agent, WR-2721 (S-2-(3-aminopro-
pylamino)ethylphosphorothioic acid) (Yuhas & Storer, 1969;
Yuhas et al., 1977, 1982), is currently undergoing clinical trial
(Constine et al., 1986; Glover et al., 1989). The monoethyl
ester of glutathione, an uncharged analogue of the most
abundant glutathione non-protein sulphydryl compound in
cells, also shows potential application as a normal tissue
protector (Teicher et al., 1988).
In 1982, Bueding noted that treatment with the anti-
schistosomal agent 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-
thione (Oltipraz) raised the cellular thiol levels in several
tissues in mice (Bueding et al., 1982). Oltipraz and other
1,2-dithiol-3-thiones have been shown to be potent inducers
of enzymes involved in maintaining levels of reduced
glutathione (De Long et al., 1986; Davies et al., 1987; Ken-
sler et al., 1987). Specifically, administration of Oltipraz or
related compounds has been shown to produce increases in
hepatic glutathione levels and glutathione-S-transferase
activities and to provide protection from the hepatotoxicity
of tetrachloromethane and acetaminophen (Ansher et al.,
1986; Davies et al., 1987). This class of compounds also has
potent anti-carcinogenic capacity providing protection
against hepatic tumorigenesis from aflatoxin B, (Kensler et
al., 1987).
The present studies were undertaken to examine the
cytotoxicity and potential of a series of 1,2-dithiol-3-thiones
and related dithioesters to act as radioprotective agents in
normally oxygenated and hypoxic EMT6 mouse mammary
tumour cells in vitro. Some of these compounds proved
highly effective protectors of normally oxygenated cells
whereas others were fair protectors of normally oxygenated
cells, but paradoxically also radiosensitised hypoxic cells.
Materials and methods
Drugs
The 1,2-dithiol-3-thiones and dithioesters shown in Table I
were synthesised by the general method reported earlier
(Foye et al., 1987). Details of the chemistry of these com-
pounds will be published later.
Cell line
The EMT6 mammary tumour cell line has been widely used
for the st7udy of antineoplastic agents (Rockwell & Kallman,
1973; Rockwell et al., 1972; Teicher et al., 1981, 1985). The
experiments described here were performed using asyn-
chronous EMT6 cells in monolayers in exponential growth in
Waymouth's medium supplemented with antibiotics (Grand
Island Biological Co., Grand Island, NY, USA) and 15%
newborn calf serum (Hyclone Laboratories, Logan, UT,
USA). This cell line has a plating efficiency of 65-80% and a
doubling time of 16-19 h in vitro (Rockwell et al., 1972).
Drug cytotoxicity
EMT6 cells were placed into T-25 flasks (Falcon Plastics).
Each flask contained approximately I x 106 cells at the time
of treatment. The drugs, in a small volume of sterile 0.9%
phosphate-buffered saline, were added to the cells in com-
plete medium in concentrations ranging from 5 to 500 fLM.
Production ofhypoxia
To produce hypoxia, flasks containing cells in complete
medium plus serum were fitted with rubber sleeve serum
stoppers and exposed to a continuously flowing 95%
nitrogen/5% CO2 humidified atmosphere for 4 h at 37°C.
Parallel flasks were maintained in 95% air/5% CO2. At this
time, the drug (0.10 ml) or vehicle (0.9% PBS, 0.10ml) was
added to the flasks by injection through the rubber stopper
without disturbing the hypoxia (Teicher et al., 1981; Teicher
& Holden, 1987).
Radiation treatment
For studies involving radiation, the flasks were placed in an
insulated chamber filled with 95% nitrogen/5% CO2
(hypoxic) or 95% air/5% CO2 (normally oxygenated) atmo-
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Table I Cytotoxicity ofdithiolthiones and dithioesters in normally oxygenated and hypoxic EMT6 cells and radioprotective effect in normally
oxygenated EMT6 cells
s-s
Dithiolthiones S
IC50 (,Ma) Radiation
Compound Normally protection
number R, R2 oxygenated Hypoxic factorb
I WNK H- 410 500 2.71
2 CsI77 CH3- 480 350 1.17
0
3 K 1C2H,OC- 800 50 1.71
4 (Oltipraz) ¢ CH3- 300 60 1.14
0 S5S ii0 5 CH,OC SCH, 350 1000 2.65
=/s~~~~~~~~~~~~~
R, 1S
Dithioesters C =C -c -SCH,
R,
IC,0 (wMa) Radiation
Compound Normally protection
number R, R2 R3 oxygenated Hypoxic factorb
6 N H - >> 1000 >> 1000 2.60
7 CN- H- 950 650 2.71
8 0 N- H- »>>1000 800 2.60
9 S N- H- 500 >>1000 2.86
10 -NH- H- 350 >> 1000 2.57
11 0 N- HC>- »1000 200 1.97
12 O N- L H3C- 480 >>1000 1.57
N
aCells in exponential growth were exposed to the drugs for I h and survival was measured by colony formation. IC") is the drug
concentration which reduced the survival of the cells by 50%; bProtection factor is defined as the ratio of the X-ray dose with protector to the
X-ray dose without protector at the level of I log of cell killing.
spheres. The cells were irradiated with a "'Cs radiation unit
(Gammacell 40, Atomic Energy of Canada Ltd) at a dose
rate of 1.05 Gymin-'. Drug-treated cells were irradiated so
that the irradiation was completed 1 h after addition of the
drug. X-ray doses of 2.5, 5.0, 10 and 15 Gy were used. A
drug concentration of 500t4M was used so that there would
be only limited toxicity from the 1,2-dithiol-3-thiones and
dithioesters.
Cell viability measurements
Cell viability was measured by the ability of single cells to
form colonies in vitro, as described previously (Teicher et al.,
1981, 1985). Following treatment, suspensions of known cell
numbers were plated in plastic Petri dishes and allowed to
grow in a 37°C incubator under standard culture conditions
for 8-10 days. After this time, macroscopic colonies were
stained with crystal violet in methanol containing 3.7% for-
maldehyde and were counted manually. Each experiment was
repeated three to five times, and each data point per experi-
ment represents the results of three different dilutions ofcells
plated in triplicate.
Calculated value
The radioprotection factor (RPF) was calculated as the ratio
of the dose of radiation to kill 1 log of normally oxygenated
cells with the drug present to dose of radiation without drug
to kill 1 log of normally oxygenated cells corrected for the
cytotoxicity of each drug.
Results
In general, 1 h exposure to the substituted 1,2-dithiol-3-
thiones and dithioesters had a relatively low level of cytotox-DITHIOLTHIONES AS RADIOPROTECTORS 19
icity toward both normally oxygenated and hypoxic EMT6
cells as measured by the IC50 (Table I). The 4-methyl-5-(2-
thienyl) analogue (compound 2) was slightly more cytotoxic
towards hypoxic EMT6 cells. The 2-ethoxycarbonyl analogue
of compound 2 (compound 3) and Oltipraz (compound 4)
were 16-fold and 5-fold more cytotoxic toward hypoxic than
normally oxygenated EMT6 cells. In contrast, of the
dithioesters, only the 3-morpholino-3-(2-thienyl) analogue
(compound 11) was significantly more cytotoxic toward
hypoxic EMT6 cells than toward normally oxygenated
EMT6 cells.
Radiation survival curves for normally oxygenated and
hypoxic EMT6 cells in vitro in the presence and absence of
1,2-dithiol-3-thiones are shown in Figure 1. The concentra-
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tion of each compound used for these radiation studies was
50011M and the agents were present for 1 h prior to and
during radiation delivery. The curves are corrected for the
small amount of drug killing. The simple 5-(2-thienyl)-1,2-
dithiol-3-thione (compound 1) was an excellent radiation
protector of normally oxygenated EMT6 cells, affording a
protection factor of 2.7 at 1 log of cell killing. The 4-methyl
derivative of compound I (compound 2) was a much less
effective radiation protector, with a protection factor of only
1.2; however, compound 2 increased the cytotoxicity of the
radiation treatments in hypoxic EMT6 cells. It appeared that
the main effect of compound 2 on the radiation response of
hypoxic EMT6 cells was to eliminate the shoulder of the
radiation survival curve. The 4-ethoxycarbonyl derivative
X-ray dose, Gray
Figure 1 Radiation survival of EMT6 mouse mammary tumour cells in the presence of 1,2-dithiol-3-thiones (compounds 1-4
from Table 1). No drug, normally oxygenated cells (0); no drug, hypoxic cells (0); 500gM drug, normally oxygenated cells (O);
500gM drug, hypoxic cells (0). The data are presented as means ± SEM (bars) for three independent experiments.20 B.A. TEICHER et al.
(compound 3) produced a good level of radiation protection
in normally oxygenated EMT6 cells, with a protective factor
of 1.7. Compound 3, like compound 1, had no effect on the
radiation survival of hypoxic EMT6 cells. The 4-methyl-5-(2-
pyrazinyl)-1,2-dithiol-3-thione (compound 4; Oltipraz), like
the other 4-methyl derivative, compound 2, increased the
killing of hypoxic EMT6 cells by radiation. The main effect
of compound 4 in hypoxic EMT6 cells also appeared to be
elimination of the shoulder of the radiation survival curve,
although there was a small increase in the slope of the
hypoxic radiation survival curve as well.
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Radiation survival curves of normally oxygenated and
hypoxic EMT6 cells in the presence and absence of
dithioesters are shown in Figure 2. Methyl 3-(1-pyrrolidino)-
2-phenylpropenedithiocarboxylate (compound 6) was an
excellent radioprotector of normally oxygenated EMT6 cells,
with a protection factor of 2.6, but had no effect on the
radiation survival of hypoxic EMT6 cells. Methyl 3-(1-
piperidino)-2-phenylpropenedithiocarboxylate (compound 7)
was also an excellent radiation protector of normally
oxygenated EMT6 cells, with a radiation protection factor of
2.7, but again there was no significant effect on the radiation
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Figure 2 Radiation survival of EMT6 mouse mammary tumour cells in the presence of dithioesters (compounds 6-9 from Table 1).
No drug, normally oxygenated cells (@); no drug, hypoxic cells (0); 500#1M drug, normally oxygenated cells (O); 500gm drug,
hypoxic cells (0). The data are presented as means ± SEM (bars) for three independent experiments.DITHIOLTHIONES AS RADIOPROTECTORS 21
survival of hypoxic EMT6 cells. The 3-morpholino derivative
(compound 8) similarly produced excellent radiation protec-
tion in normally oxygenated EMT6 cells, with a protection
factor of 2.6. Unlike compounds 6 and 1, compound 8
increased the cytotoxicity of radiation towards hypoxic
EMT6 cells to a small extent. The 3-thiomorpholino
derivative (compound 9) was the most effective radioprotec-
tor of normally oxygenated EMT6 cells tested, with a protec-
tion factor of 2.9, and compound 9 did not alter the radia-
tion response of hypoxic EMT6 cells.
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Radiation survival curves for normally oxygenated and
hypoxic EMT6 cells in the presence and absence of the
remaining compounds are shown in Figure 3. Compound 5,
the salt formed by the reaction of methyl iodide with the
corresponding 1,2-dithiol-3-thione, was a highly effective
radioprotective agent of normally oxygenated EMT6 cells,
with a protection factor of 2.6 Compound S had no effect on
the radiation survival of hypoxic EMT6 cells. Methyl 3-
cyclohexylamino-2-phenylpropenedithiocarboxylate (compound
10) also had a highly effective radiation protection factor of
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Figure 3 Radiation survival of EMT6 mouse mammary tumour cells in the presence of a 1,2-dithiolium salt (compound 5 from
Table 1) and of substituted dithioesters (compounds 10-12 from Table 1). No drug, normally oxygenated cells (0); no drug,
hypoxic cells (0); 500jiM drug, normally oxygenated cells (-); 500tLM drug, hypoxic cells (0). The data are presented as
means ± SEM (bars) for three independent experiments.22 B.A. TEICHER et al.
2.6 while producing no change in the radiosensitivity of
hypoxic EMT6 cells. Methyl 3-morpholino-3-(2-thienyl)-2-
methylpropenedithiocarboxylate (compound 11) was an
effective radiation protective agent, with a radioprotective
factor of 2.0, but again did not alter the radiation sensitivity
of hypoxic EMT6 cells. Methyl 3-morpholino-3-(2-pyrazinyl)-
2-methylpropenedithiocarboxylate (compound 12) was a
moderately effective radioprotective agent, with a resulting
radiation protection factor of 1.6 However, this compound
also increased the radiosensitivity of hypoxic EMT6 cells,
although to a lesser extent.
Discussion
1,2-Dithiol-3-thiones have demonstrated chemoprotective
actions against a wide variety of structurally diverse car-
cinogens (Wattenberg & Bueding, 1986; Kensler et al., 1987;
Helmes et al., 1989). These compounds have been used
medicinally as antischistosomal agents, choleretics, and to
stimulate salivary secretion (Lozac'h & Stavaux, 1980;
Bueding et al., 1982; Hausler, 1979; Archer, 1985).
We have examined the radioprotective potential of four
1,2-dithiol-3-thiones and seven dithioesters which are chemi-
cally derived from dithiolthiones. Two of the 1,2-dithiol-3-
thiones were effective radioprotectors of normally oxygenated
EMT6 cells and two showed very little radioprotective
activity. Both ineffective compounds had 4-methyl substi-
tuents and both of these agents increased the radiation sen-
sitivity of hypoxic EMT6 cells quite markedly. It may be that
having a hydrogen in the 4-position allows ring opening of
the 1,2-dithiol-ring to occur providing a substantial increase
in non-protein sulphydryl within cells and thus radioprotec-
tion. A methyl group in the 4-position, on the other hand,
may block the ring opening, leading to an inactive molecule.
The mechanism for the hypoxic cell selectivity of compounds
3 and 4 remains to be elucidated. The dithioesters were, in
general, less cytotoxic than the 1,2-dithiol-3-thiones but also
highly effective radiation protective agents. It may be
envisioned that oxidative metabolism of the dithioesters
could lead to the release of a thiomethylating species, a
potent radical scavenger.
Since most normal tissues are well oxygenated, it is the
normally oxygenated EMT6 cells which are the most appro-
priate model for a radioprotector in a cell culture system.
Our work with these agents is continuing and we are examin-
ing the efficacy of selected examples as normal tissue radia-
tion protectors in vivo.
This work was supported by grants nos. PO1 CA38493 and
PO1 CA19589 from the National Cancer Institute.
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